RCS - Abingdon Health PLC - Update on Partnership with 4TEEN4 Pharmaceuticals

Abingdon HealthAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260506:nRSF1323Da&default-theme=true

RNS Number : 1323D  Abingdon Health PLC  06 May 2026

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

Update on Partnership with 4TEEN4 Pharmaceuticals

 

York, UK and Madison, WI, USA, 6 May 2026: Abingdon Health plc (AIM: ABDX)
(OTCQB: ABDXF), a leading international developer, manufacturer and regulatory
services provider for rapid diagnostic tests and med-tech, provides an update
on its partnership with 4TEEN4 Pharmaceuticals GmbH ("4TEEN4"), a German
biopharmaceutical company developing invobenitug (procizumab, AK1967), a
first-in-class antibody therapy for life-threatening cardiogenic and septic
shock.

 

This partnership was first announced via RNS on 12 June 2025
(https://www.londonstockexchange.com/news-article/ABDX/eu2m-contract-win-for-companion-diagnostic-test/17081832)
, without giving details of the customer or project at that time for
confidentiality reasons.

 

As legal manufacturer and CDMO partner, Abingdon Health is developing DPP3
InvoSelect, a lateral flow-based companion diagnostic (CDx) designed to
identify the patients most likely to benefit from this targeted therapy.

 

The project brings together Abingdon Health's core capabilities:

·    Lateral Flow Development: designing a scalable, easy-to-use assay
with a customised reader for clear, unambiguous quantification of cDPP3 at the
point of care.

·    Regulatory Expertise: proactively engaging with regulatory agencies
for technical advice and ensuring CDx strategy is tightly aligned with the
drug development pathway.

·    Manufacturing at Scale: building a test engineered for global
distribution and consistent quality from day one.

·    Synchronised Co-development: matching every CDx milestone to the
drug's clinical timeline, because in a project like this, the two cannot be
decoupled.

 

The challenge of synchronising diagnostic and therapeutic development is
incredibly complex and demands experienced technical capability, deep
regulatory understanding, genuine partnership, and rigorous project
management.

 

The full case study is available at: Case Study: 4TEEN4 Companion Diagnostic
Partnership - Abingdon Health plc
(https://www.abingdonhealth.com/4teen4-companion-diagnostic-partnership-case-study/)

 

The Head of CDx at 4TEEN4 Pharmaceuticals commented: "The technical expertise
and regulatory support provided by Abingdon Health have been invaluable in
advancing our companion diagnostic project. Their commitment and collaborative
approach have brought us significantly closer to delivering a life-saving
therapy for patients in critical shock."

 

Chris Yates, Chief Commercial Officer at Abingdon Health plc, commented:
"Companion diagnostics that are tightly co-developed alongside a therapeutic
aren't just a technical challenge; they represent a genuine opportunity to
change patient outcomes. We're proud to be 4TEEN4's CDMO partner on this
programme, and the progress we've made together in aligning our CDx milestones
with their clinical pathway reflects the depth of collaboration both teams are
committed to. We look forward to continuing to advance this project toward the
patients who need it most."

 

Any shareholders wishing to keep up to date with Abingdon Health news, please
email abingdon@walbrookpr.com

 

Enquiries:

 

 Abingdon Health plc                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Hand, Executive Chairman                                                         Via Walbrook PR

 Tom Hayes, CFO

 Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser)                    Tel: +44 (0)20 7220 0500
 Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Abingdon Health

 

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Group's CDMO
(https://www.abingdonhealth.com/services/lateral-flow-cdmo-development)
(Contract Development and Manufacturing Organisation) expertise offers lateral
flow product development
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
, regulatory strategy support, technology transfer and manufacturing services
(https://www.abingdonhealth.com/services/lateral-flow-scale-up-technical-transfer)
for customers looking to develop new assays or transfer existing
laboratory-based assays to a lateral flow format.  Abingdon Health has the
internal capabilities to take lateral flow projects, in areas such as
infectious disease and clinical testing
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
, including companion diagnostics
(https://www.abingdonhealth.com/services/companion-diagnostics-ivd-cdmo) ,
animal health and environmental testing, from initial concept through to
routine manufacturing; from idea to commercial success.

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences)
and IVDeology, provide a broad range of regulatory services to the in vitro
diagnostic and wider medical device industry, to support customers in bringing
products to market across a range of territories including the USA, EU and the
UK. Its consultancy services range from design, implementation and maintenance
of quality management systems, preparation of technical files for regulatory
approvals, part-time and interim management support, auditing both internal
and external, management reviews and presentations, training and mentoring.
 The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing
and performance evaluation
(https://www.abingdonhealth.com/services/performance-evaluation-services/) to
generate the required technical and data for regulatory approval for lateral
flow and other in vitro diagnostic assays from its Doncaster, England
facilities.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
laboratories in Doncaster, England and laboratories and commercial offices in
Madison, Wisconsin, USA.

 

Abingdon Health's brochures
(https://www.abingdonhealth.com/knowledge-centre/brochures-guides)  outlines
the comprehensive support the Group can now provide to its international
customers.  For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)
.

 

LEI - 213800XFI4WV3FBILO20

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUPWAUPQGBA



            Copyright 2019 Regulatory News Service, all rights reserved